Literature DB >> 8513661

Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.

J M Ford1, C A Truman, G K Wilcock, C J Roberts.   

Abstract

OBJECTIVE: To assess the value of serum measurements of tacrine hydrochloride and its metabolite in predicting risk of adverse reaction in Alzheimer's disease.
METHODS: The study was an outpatient-based controlled clinical trial. Study subjects were 35 female and 31 male patients who were receiving 50 to 150 mg tacrine hydrochloride per day.
RESULTS: Serum concentration of tacrine hydrochloride and ratio of tacrine hydrochloride to metabolite were significantly higher in the 45 patients with symptomatic adverse effects (p < 0.001). The tacrine hydrochloride to metabolite ratio was significantly higher (p < 0.05) in the 30 patients in whom abnormal liver function developed, but concentration of tacrine hydrochloride was not significantly higher. Women showed a higher incidence of adverse effects (p < 0.05), and tacrine hydrochloride concentrations were higher (p < 0.05). Tacrine hydrochloride concentration and tacrine hydrochloride to metabolite ratio were higher in both men and women in whom adverse effects developed.
CONCLUSION: Tacrine hydrochloride concentration is valuable in predicting the development of adverse effects, and its measurement may improve the use of the drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513661     DOI: 10.1038/clpt.1993.91

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Sex and age differences in the pharmacokinetics of alosetron.

Authors:  K M Koch; J L Palmer; N Noordin; J J Tomlinson; C Baidoo
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease.

Authors:  P M Mäkelä; C A Truman; J M Ford; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment.

Authors:  P Glue; R P Clement
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 9.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

10.  Tacrine and lecithin in Alzheimer's disease. Serum tacrine concentrations too low.

Authors:  C Roberts; P Mäkelä; J Ford; C Truman
Journal:  BMJ       Date:  1994-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.